Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126277811 | 12627781 | 1 | I | 2015 | 20160725 | 20160806 | 20160806 | EXP | AT-ACCORD-042860 | ACCORD | PORPACZY E, MAYERHOEFER M, SALZER-MUHAR U, JAEGER U. LYMPHOMA IN DANON DISEASE WITH CHRONIC RHABDOMYOLYSIS TREATED WITH EPOCH-R: A CASE REPORT. MEDICINE (BALTIMORE). 2016 JUL; 95(29):E4237. | 22.00 | YR | M | Y | 0.00000 | 20160806 | MD | AT | AT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126277811 | 12627781 | 1 | PS | TACROLIMUS. | TACROLIMUS | 1 | 91195 | 2.5 | MG | ||||||||||
| 126277811 | 12627781 | 2 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | REDUCED-DOSE AT 1 M^2 INSTEAD OF 1.68 M^2 | U | 74513 | ||||||||||
| 126277811 | 12627781 | 3 | SS | DOXORUBICIN | DOXORUBICIN | 1 | REDUCED-DOSE AT 1 M^2 INSTEAD OF 1.68 M^2??CONTINUOUS ADMINISTRATION OVER 4 DAYS | U | 200750109 | ||||||||||
| 126277811 | 12627781 | 4 | SS | CYCLOPHOSPHAMIDE/CYCLOPHOSPHAMIDE MONOHYDRATE | CYCLOPHOSPHAMIDE | 1 | REDUCED-DOSE AT 1 M^2 INSTEAD OF 1.68 M^2 | U | 0 | ||||||||||
| 126277811 | 12627781 | 5 | SS | VINCRISTINE | VINCRISTINE | 1 | REDUCED-DOSE AT 1 M^2 INSTEAD OF 1.68 M^2 | U | 0 | ||||||||||
| 126277811 | 12627781 | 6 | SS | PREDNISONE. | PREDNISONE | 1 | REDUCED-DOSE AT 1 M^2 INSTEAD OF 1.68 M^2 | U | 0 | ||||||||||
| 126277811 | 12627781 | 7 | SS | RITUXIMAB | RITUXIMAB | 1 | REDUCED-DOSE AT 1 M^2 INSTEAD OF 1.68 M^2 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126277811 | 12627781 | 1 | Immunosuppression |
| 126277811 | 12627781 | 2 | Diffuse large B-cell lymphoma |
| 126277811 | 12627781 | 3 | Diffuse large B-cell lymphoma |
| 126277811 | 12627781 | 4 | Diffuse large B-cell lymphoma |
| 126277811 | 12627781 | 5 | Diffuse large B-cell lymphoma |
| 126277811 | 12627781 | 6 | Diffuse large B-cell lymphoma |
| 126277811 | 12627781 | 7 | Diffuse large B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126277811 | 12627781 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126277811 | 12627781 | Abdominal pain | |
| 126277811 | 12627781 | Febrile neutropenia | |
| 126277811 | 12627781 | Off label use | |
| 126277811 | 12627781 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126277811 | 12627781 | 2 | 20150423 | 0 | ||
| 126277811 | 12627781 | 3 | 20150423 | 0 | ||
| 126277811 | 12627781 | 4 | 20150423 | 0 | ||
| 126277811 | 12627781 | 5 | 20150423 | 0 | ||
| 126277811 | 12627781 | 6 | 20150423 | 0 | ||
| 126277811 | 12627781 | 7 | 20150423 | 0 |